Labiotech.eu

More News! 15 Jul 2017

Speculative Biology in Art: How will Life Look like in the Future?

The first solo exhibition of Turkish artist Pinar Yoldas imagines a future where biology is shaped by climate change and plastic pollution. Last week in Amsterdam opened Carboniferous, a solo bioart exhibition by Pinar Yoldas focusing on speculative biology. This concept revolves around imagining how life will evolve according to predictions of how the planet’s future ecosystems […]

July 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 13 Jul 2017

Video: How to Access EU Funding as an Innovative Biotech

Two experts, one success story. From the European Commission to the European Investment Bank, our experts told us what to do to access EU funding as an innovative and young Biotech company! This Refresh Expert Track kicked off with the Head of Unit at the European Commission, Cornelius Schmaltz, who introduced the focus for health research […]

July 13, 2017 - 2 minutesmins - By External Contributor

News and Trends 13 Jul 2017

Why European Biotech Startups Should Attend American Conferences!

We all know conferences are important. To be on the same page, let’s brainstorm the word. What comes to mind? A long list of associations – networking, partnering, businesses, meetings, new people, knowledge, presentations, talks, panels, companies. We could go on and on – one thing is clear: they are one of the most effective […]

July 13, 2017 - 6 minutesmins - By External Contributor

Interview 13 Jul 2017

Meet Denmark’s Youngest Professor and Serial Synbio Entrepreneur

Philip sat down to chat with Professor and serial entrepreneur Morten Sommer about his career in the second Labiotech Hangout. At 35, Morten Sommer is not only the youngest full professor ever in Denmark but also the entrepreneur behind a number of synbio-based companies. For Labiotech’s second Hangout on June 29th, Philip probed his thoughts […]

July 13, 2017 - 4 minutesmins - By Evelyn Warner

inflammatory disease imperial college london macrophage

News and Trends 12 Jul 2017

British Researchers “Calm Down” Macrophages to treat Inflammation

Imperial College London and Ergon Pharmaceuticals have a new enzyme target to treat inflammatory disease by reducing the activity of macrophages. Researchers at Imperial College London have developed a method to reprogram macrophages and reduce their inflammatory activity. The approach, published in Nature Communications, proved to reduce by more than half inflammation in the joints […]

July 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

genetically modified mosquitoes Oxitec Netherlands

News and Trends 12 Jul 2017

Update: France and the Netherlands deem Oxitec’s GM Mosquitoes Safe for Release

Update (12/07/2017): France’s High Council for Biotechnology (HCB) has also backed the use, with caution, of genetically modified mosquitoes in France. Oxitec expects the report published by the HCB will help shape the policy to regulate the genetically engineered insects in France and eventually allow testing the technology in the French Caribbean. Originally published on 07/07/2017 A […]

July 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Erytech pharma Queens university red blood cells

News and Trends 12 Jul 2017

French Biotech and Canadian University to treat Rare Disease with Red Blood Cells

Erytech Pharma has entered a partnership with Queen’s University to treat the rare disease arginase-1 deficiency using engineered red blood cells. Erytech, based in Lyon, is known for its unique technology for drug delivery. Its most advanced program, in Phase IIb for metastatic pancreatic cancer, employs red blood cells engineered to produce the enzyme L-asparaginase, which depletes […]

July 12, 2017 - 1 minutemin - By Clara Rodríguez Fernández

In Depth 12 Jul 2017

Genomic Testing in Oncology: From Single Genes to Whole Genomes

Personalized medicine would be nothing without genomic testing tools. Here’s an overview of how the field has rapidly evolved in the past years. BRCA (BReast CAncer) is one of the most famous gene variants for breast cancer testing. But aside from being a game-changer from a scientific perspective, it also changed the laws of genomic testing. […]

July 12, 2017 - 5 minutesmins - By Timothé Cynober

Interview 11 Jul 2017

The Advantage for the First Mover in NASH is Limited, says Genfit

After we reviewed NASH earlier this year, Genfit’s CSO, Dean Hum, came to speak at Refresh about his company’s strategy in the space. As CSO of Genfit, Dean Hum coordinates the company’s R&D efforts to be first to market in NASH, which represent an untapped market of €37B. The company is counting on its lead […]

July 11, 2017 - 4 minutesmins - By Evelyn Warner

News and Trends 11 Jul 2017

Finnish AI Biotech Raises €14M to Open the Bottleneck of Next-Generation Sequencing

Blueprint Genetics has raised €14M to boost its genetic diagnostics platform, using artificial intelligence to interpret next-generation sequencing data. Based in Helsinki, Finland, Blueprint Genetics is a startup that addresses the main bottleneck of genetic testing through next-generation sequencing (NGS), the interpretation of massive volumes of data, with the aid of artificial intelligence (AI). Its […]

July 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Microbiome Diagnostics Partners Enterome Nestle e1517266503234

News and Trends 11 Jul 2017

Enterome and Nestle Launch a New Microbiome Diagnostics Company

Microbiome Diagnostics Partners will develop diagnostics tests with Enterome’s microbiome platform IP and a €20M investment from Nestlé. Nestlé Health Science and Enterome have created Microbiome Diagnostics Partners (MDP) as a joint venture split 50% between both parties. Nestlé has invested €20M for its stake in the new company as well as the exclusive option to commercialize […]

July 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 11 Jul 2017

Novartis largely dodged deaths from its CAR-T therapy, but FDA still has safety concerns

Editor’s Note: Novartis did note a death from cerebral hemorrhage in its hearing with the FDA yesterday. With the application review hearing set for tomorrow, the FDA has shared its thoughts on Novartis’ CAR-T candidate. Up front are serious safety concerns. Novartis’ CTL019, or Tisagenlecleucel, wowed the audience at ASH last fall with a stellar 82% […]

July 11, 2017 - 3 minutesmins - By Evelyn Warner

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Speculative Biology in Art: How will Life Look like in the Future?

Video: How to Access EU Funding as an Innovative Biotech

Why European Biotech Startups Should Attend American Conferences!

Meet Denmark’s Youngest Professor and Serial Synbio Entrepreneur

British Researchers “Calm Down” Macrophages to treat Inflammation

Update: France and the Netherlands deem Oxitec’s GM Mosquitoes Safe for Release

French Biotech and Canadian University to treat Rare Disease with Red Blood Cells

Genomic Testing in Oncology: From Single Genes to Whole Genomes

The Advantage for the First Mover in NASH is Limited, says Genfit

Finnish AI Biotech Raises €14M to Open the Bottleneck of Next-Generation Sequencing

Enterome and Nestle Launch a New Microbiome Diagnostics Company

Novartis largely dodged deaths from its CAR-T therapy, but FDA still has safety concerns

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!